Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China.
10.1097/CM9.0000000000003125
- Author:
Dengfeng WANG
1
;
Xunwei SHI
1
;
Jiao PEI
2
;
Can ZHANG
1
;
Liping PENG
1
;
Jie ZHANG
1
;
Jing ZHENG
1
;
Chunrong PENG
1
;
Xiaoqiao HUANG
1
;
Xiaoshi LIU
1
;
Hong LIU
1
;
Guonan ZHANG
1
Author Information
1. Department of Gynecologic Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China.
2. Department of Clinical Research, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China.
- Publication Type:Journal Article
- Keywords:
First-line maintenance therapy;
Ovarian cancer;
PARP inhibitor;
PFS;
Platinum-sensitive recurrent maintenance therapy;
Real-world study
- MeSH:
Humans;
Female;
Ovarian Neoplasms/drug therapy*;
Piperazines/therapeutic use*;
Middle Aged;
Retrospective Studies;
Phthalazines/therapeutic use*;
Piperidines/therapeutic use*;
Indazoles/therapeutic use*;
Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use*;
Adult;
Aged;
China;
Neoplasm Recurrence, Local/drug therapy*;
Progression-Free Survival
- From:
Chinese Medical Journal
2025;138(10):1194-1201
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Poly adenosine-diphosphate-ribose polymerase (PARP) inhibitors (PARPi) have been approved to act as first-line maintenance (FL-M) therapy and as platinum-sensitive recurrent maintenance (PSR-M) therapy for ovarian cancer in China for >5 years. Herein, we have analyzed the clinical-application characteristics of olaparib and niraparib in ovarian cancer-maintenance therapy in a real-world setting to strengthen our understanding and promote their rational usage.
METHODS:A retrospective chart review identified patients with newly diagnosed or platinum-sensitive recurrent ovarian cancer, who received olaparib or niraparib as maintenance therapy at Sichuan Cancer Hospital between August 1, 2018, and December 31, 2021. Patient medical records were reviewed. We grouped and analyzed patients based on the type of PARPi they used (the olaparib group and the niraparib group) and the line of PARPi maintenance therapy (the FL-M setting and the PSR-M setting). The primary endpoint was the 24-month progression-free survival (PFS) rate.
RESULTS:In total, 131 patients (olaparib: n = 67, 51.1%; niraparib: n = 64, 48.9%) were enrolled. Breast cancer susceptibility genes ( BRCA ) mutations ( BRCA m) were significantly less common in the niraparib group than in the olaparib group [9.4% (6/64) vs . 62.7% (42/67), P <0.001], especially in the FL-M setting [10.4% (5/48) vs . 91.4% (32/35), P <0.001]. The 24-month progression-free survival (PFS) rates in the FL-M and PSR-M settings were 60.4% and 45.7%, respectively. In patients with BRCA m, the 24-month PFS rates in the FL-M and PSR-M settings were 62.2% and 72.7%, respectively.
CONCLUSIONS:Olaparib and niraparib were effective in patients with ovarian cancer without any new safety signals except for skin pigmentation. In patients with BRCA m, the 24-month PFS of the PARPi used in the PSR-M setting was even higher than that used in the FL-M setting.
